TFFP (tffpharma.com) יחס שווי שוק לשווי בספרים
The strategic growth of TFF Pharmaceuticals (TFFP) relies on partnerships with vaccine developers through licensing agreements. The company's current P/BV multiple visualizes this trend, where 0.07 shapes the current metric. Revenues are based on royalties from Big Pharma for the use of patents, while success depends on the bioavailability of powder forms and the number of drug delivery contracts.
%3A%20%D7%A9%D7%95%D7%95%D7%99%20%D7%A9%D7%95%D7%A7%20%D7%91%D7%99%D7%97%D7%A1%20%D7%9C%D7%A0%D7%9B%D7%A1%D7%99%D7%9D%20%D7%A0%D7%A7%D7%99%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mvq8bmkb.8d-7aozthc&start=20220704&end=20261027&filename=GURU_Markets_-_TFFP_-_TFF-Pharmaceuticals_-_Market-Capitalization-to-Net-Assets "TFFP יחס שווי שוק לערך בספרים TFF Pharmaceuticals, Inc (04.07.2022 - 21.12.2024) | 👁️GURU.Markets👁️")
פילוחי מדדים פיננסיים ומדדי שוק עבור TFF Pharmaceuticals Inc. (TFFP)
This ratio determines the strategic control premium by comparing the current market value of the business with its book value. The metric's dynamics reflect the real-time assessment of investors to shifting fundamental expectations between reporting periods. By analyzing the deviation of market valuation from book value, one can identify the extent of the overpayment for assets. For TFF Pharmaceuticals (TFFP), a high premium is driven by the potential of thin-film freezing technology. The indicator's growth will depend on the success of voriconazole clinical trials and the execution of licensing agreements.